Overview Dividends

(KVUE) Kenvue - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US49177J1025

Pain Care, Digestive Health, Skin Care, Hair Care, Oral Care, Baby Care

KVUE EPS (Earnings per Share)

EPS Growth (3Y CAGR): -39.33%
EPS Trend (3Y Correlation): -73.8%

KVUE Revenue

Revenue Growth (3Y CAGR): 0.48%
Revenue Trend (3Y Correlation): -12.1%

Description: KVUE Kenvue

Kenvue Inc. (NYSE:KVUE) is a consumer health company with a global presence, operating in multiple regions including the United States, Europe, and Asia-Pacific. The company is organized into three main segments: Self Care, Skin Health and Beauty, and Essential Health, offering a diverse range of products under well-known brand names such as Tylenol, Neutrogena, and Listerine.

The companys product portfolio is focused on consumer health and wellness, with a presence in various categories including pain care, skin health, oral care, and womens health. With a strong brand portfolio, Kenvue Inc. is well-positioned to capitalize on trends in the personal care products industry. Key performance indicators (KPIs) to watch include revenue growth, gross margin expansion, and operating cash flow generation. The companys return on equity (RoE) of 10.42% indicates a moderate level of profitability. Additionally, the forward P/E ratio of 19.12 suggests that the market expects earnings growth in the future.

To further evaluate Kenvue Inc.s performance, it is essential to monitor its segment-wise revenue contribution, geographic expansion, and product innovation pipeline. The companys ability to maintain its market share and expand its presence in emerging markets will be crucial in driving long-term growth. Other relevant KPIs include the companys dividend yield, debt-to-equity ratio, and operating margin. A thorough analysis of these metrics will provide a comprehensive understanding of Kenvue Inc.s financial health and growth prospects.

KVUE Stock Overview

Market Cap in USD	41,241m
Sub-Industry	Personal Care Products
IPO / Inception	2023-05-04

KVUE Stock Ratings

Growth Rating	-11.8%
Fundamental	56.3%
Dividend Rating	63.7%
Return 12m vs S&P 500	-15.6%
Analyst Rating	3.42 of 5

KVUE Dividends

Dividend Yield 12m	3.86%
Yield on Cost 5y	3.33%
Annual Growth 5y	42.30%
Payout Consistency	100.0%
Payout Ratio	92.5%

KVUE Growth Ratios

Growth Correlation 3m	-3.4%
Growth Correlation 12m	-2.9%
Growth Correlation 5y	20.3%
CAGR 5y	-7.31%
CAGR/Max DD 5y	-0.22
Sharpe Ratio 12m	-0.60
Alpha	-8.60
Beta	0.260
Volatility	25.02%
Current Volume	10307.4k
Average Volume 20d	16054k
Stop Loss	20 (-3.4%)
Signal	0.39

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (676.0m TTM) > 0 and > 6% of Revenue (6% = 908.5m TTM)

FCFTA 0.06 (>2.0%) and ΔFCFTA -0.68pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -0.89% (prev -0.36%; Δ -0.52pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.08 (>3.0%) and CFO 2.09b > Net Income 676.0m (YES >=105%, WARN >=100%)

Net Debt (7.54b) to EBITDA (3.10b) ratio: 2.43 <= 3.0 (WARN <= 3.5)

Current Ratio 0.98 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (1.93b) change vs 12m ago 0.36% (target <= -2.0% for YES)

Gross Margin 58.05% (prev 57.45%; Δ 0.59pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 56.52% (prev 58.52%; Δ -2.00pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 7.05 (EBITDA TTM 3.10b / Interest Expense TTM 392.0m) >= 6 (WARN >= 3)

Altman Z'' 0.64

(A) -0.00 = (Total Current Assets 5.85b - Total Current Liabilities 5.99b) / Total Assets 27.13b

(B) -0.01 = Retained Earnings (Balance) -136.0m / Total Assets 27.13b

(D) -0.01 = Book Value of Equity -136.0m / Total Liabilities 16.40b

Total Rating: 0.64 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 56.25

1. Piotroski 4.50pt = -0.50

2. FCF Yield 3.35% = 1.67

3. FCF Margin 10.79% = 2.70

4. Debt/Equity 0.80 = 2.19

5. Debt/Ebitda 2.78 = -1.44

6. ROIC - WACC 4.77% = 5.97

7. RoE 6.58% = 0.55

8. Rev. Trend -12.09% = -0.60

9. Rev. CAGR 0.48% = 0.06

10. EPS Trend -73.84% = -1.85

11. EPS CAGR -39.33% = -2.50

What is the price of KVUE shares?

As of August 31, 2025, the stock is trading at USD 20.71 with a total of 10,307,449 shares traded.
Over the past week, the price has changed by -4.16%, over one month by -5.69%, over three months by -11.33% and over the past year by -1.21%.

Is Kenvue a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Kenvue is currently (August 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 56.25 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of KVUE is around 19.99 USD . This means that KVUE is currently overvalued and has a potential downside of -3.48%.

Is KVUE a buy, sell or hold?

Kenvue has received a consensus analysts rating of 3.42. Therefor, it is recommend to hold KVUE.

Strong Buy: 3
Buy: 2
Hold: 14
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the KVUE price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	22.8	10.1%
Analysts Target Price	24.3	17.2%
ValueRay Target Price	21.8	5.1%

Last update: 2025-08-21 02:48

KVUE Fundamental Data Overview

Market Cap USD = 41.24b (41.24b USD * 1.0 USD.USD)
CCE Cash And Equivalents = 1.07b USD (Cash only, last quarter)
P/E Trailing = 28.6533
P/E Forward = 21.0526
P/S = 2.7238
P/B = 3.8435
P/EG = 1.177
Beta = 0.785
Revenue TTM = 15.14b USD
EBIT TTM = 2.77b USD
EBITDA TTM = 3.10b USD
Long Term Debt = 7.06b USD (from longTermDebt, last quarter)
Short Term Debt = 1.55b USD (from shortLongTermDebt, last quarter)
Debt = 8.61b USD (Calculated: Short Term 1.55b + Long Term 7.06b)
Net Debt = 7.54b USD (from netDebt column, last quarter)
Enterprise Value = 48.78b USD (41.24b + Debt 8.61b - CCE 1.07b)
Interest Coverage Ratio = 7.05 (Ebit TTM 2.77b / Interest Expense TTM 392.0m)
FCF Yield = 3.35% (FCF TTM 1.63b / Enterprise Value 48.78b)
FCF Margin = 10.79% (FCF TTM 1.63b / Revenue TTM 15.14b)
Net Margin = 4.46% (Net Income TTM 676.0m / Revenue TTM 15.14b)
Gross Margin = 58.05% ((Revenue TTM 15.14b - Cost of Revenue TTM 6.35b) / Revenue TTM)
Tobins Q-Ratio = -358.7 (set to none) (Enterprise Value 48.78b / Book Value Of Equity -136.0m)
Interest Expense / Debt = 0.94% (Interest Expense 81.0m / Debt 8.61b)
Taxrate = 27.21% (from yearly Income Tax Expense: 385.0m / 1.42b)
NOPAT = 2.01b (EBIT 2.77b * (1 - 27.21%))
Current Ratio = 0.98 (Total Current Assets 5.85b / Total Current Liabilities 5.99b)
Debt / Equity = 0.80 (Debt 8.61b / last Quarter total Stockholder Equity 10.73b)
Debt / EBITDA = 2.78 (Net Debt 7.54b / EBITDA 3.10b)
Debt / FCF = 5.27 (Debt 8.61b / FCF TTM 1.63b)
Total Stockholder Equity = 10.27b (last 4 quarters mean)
RoA = 2.49% (Net Income 676.0m, Total Assets 27.13b )
RoE = 6.58% (Net Income TTM 676.0m / Total Stockholder Equity 10.27b)
RoCE = 15.95% (Ebit 2.77b / (Equity 10.27b + L.T.Debt 7.06b))
RoIC = 10.66% (NOPAT 2.01b / Invested Capital 18.88b)
WACC = 5.88% (E(41.24b)/V(49.85b) * Re(6.97%)) + (D(8.61b)/V(49.85b) * Rd(0.94%) * (1-Tc(0.27)))
Shares Correlation 5-Years: 80.0 | Cagr: 0.50%
Discount Rate = 6.97% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 74.39% ; FCFE base≈1.69b ; Y1≈1.34b ; Y5≈890.7m
Fair Price DCF = 8.64 (DCF Value 16.58b / Shares Outstanding 1.92b; 5y FCF grow -24.82% → 3.0% )
Revenue Correlation: -12.09 | Revenue CAGR: 0.48%
Rev Growth-of-Growth: -2.94
EPS Correlation: -73.84 | EPS CAGR: -39.33%
EPS Growth-of-Growth: -33.70

Additional Sources for KVUE Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle